About Event
Why Attend the 2nd Hit ID Summit?
Ready to shake up your hit discovery game? The 2nd Hit ID Summit is your go-to hub for drug hunters looking to crack through targets and uncover quality leads. Join 60+ renowned scientists – chemists, biophysicists, and beyond – for three high-energy days diving into AI-powered screening, DELs, fragments, and smarter chemical libraries to excel in the discovery of high-quality leads.
Exchange insightful case studies on existing and novel methods, tackle protein-protein headaches, and dig into trick mRNA and receptor targets. Additionally, you will get to experience our hands-on workshops unveiling a step-by-step guide to build a hit discovery funnel and harnessing the latest computational tools to amplify your compound screening abilities.
Data-Driven Case Studies You Can’t Miss:
Integrate assay platforms with cancer biology to eliminate off-target effects and enhance lead confidence for hit validation on DHX9 and KIF18A with Accent Therapeutics
Combine chemical clustering, predictive ML models, and promiscuity profiling to guide hit triaging for strategic prioritization of chemical series with Johnson & Johnson
Leverage structure-guided design in phage display to boost hit rates and confirm binding activity for high-quality starting points with Bicycle Therapeutics
Apply multi-faceted screening beyond cell-based assays to address biologic-specific challenges and improve physiological translation for hit discovery with Genentech
Promote 3D screening of diverse effector-target-glue combinations to assess molecular interactions and enable modality-driven discovery for complex targets with A-Alpha Bio
Who Will You Meet?
This industry-definitive, hit ID-focused forum is your golden ticket to join and network with 60+ Vice Presidents, Directors, and Leaders of Medicinal Chemistry, In Silico Discovery, Biophysics, Structural Biology, and Molecular Biology – all under one roof – with the shared interest of improving hit identification and screening strategies to effectively screen hits for hard-to-drug targets.
